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Abstract
Background: Multicomponent therapeutics offer bright prospects for the control of complex diseases in a
synergistic manner. However, finding ways to screen the synergistic combinations from numerous pharmacological
agents is still an ongoing challenge.
Results: In this work, we proposed for the first time a “network target”-based paradigm instead of the traditional
“single target"-based paradigm for virtual screening and established an algorithm termed NIMS (Network target-
based Identification of Multicomponent Synergy) to prioritize synergistic agent combinations in a high throughput
way. NIMS treats a disease-specific biological network as a therapeutic target and assumes that the relationship
among agents can be transferred to network interactions among the molecular level entities (targets or responsive
gene products) of agents. Then, two parameters in NIMS, Topology Score and Agent Score, are created to evaluate
the synergistic relationship between each given agent combinations. Taking the empirical multicomponent system
traditional Chinese medicine (TCM) as an illustrative case, we applied NIMS to prioritize synergistic agent pairs from
63 agents on a pathological process instanced by angiogenesis. The NIMS outputs can not only recover five
known synergistic agent pairs, but also obtain experimental verification for synergistic candidates combined with,
for example, a herbal ingredient Sinomenine, which outperforms the meet/min method. The robustness of NIMS
was also showed regarding the background networks, agent genes and topological parameters, respectively.
Finally, we characterized the potential mechanisms of multicomponent synergy from a network target perspective.
Conclusions: NIMS is a first-step computational approach towards identification of synergistic drug combinations
at the molecular level. The network target-based approaches may adjust current virtual screen mode and provide a
systematic paradigm for facilitating the development of multicomponent therapeutics as well as the modernization
of TCM.
Background
Multicomponent therapeutics, in which two or more
agents interact with multiple targets simultaneously, is
considered as a rational and efficient form of therapy
designed to control complex diseases [1,2]. Here “agent”
refers to medicinal entities, chemical substances, herbs
and the like with pharmacological or biological activities.
One of the fundamental advantages of multicomponent
therapeutics is the production of “synergy”,t h a ti s ,t h e
combinational effect to be greater than the sum of the
individual effects, making multicomponent therapeutics
a systematic approach, rather than the reductionism of
an additive effect. Understanding multicomponent
synergy is critical for developing a novel strategy to con-
quer complex diseases. It is believed that combinations
of agents can effectively reduce side effects and improve
adaptive resistance, thereby increasing the likelihood of
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any medium, provided the original work is properly cited.conquering complex diseases, such as cancer, in a syner-
gistic manner [3].
Evaluation of multicomponent synergy is usually
implemented experimentally in a case-by-case approach
[4] and evaluated using the reference models of additi-
vism to recognize synergy such as the Bliss indepen-
dence model [5], the Loewe additivism model [6] and
the Combination Index theorem [7]. However, large
number of possible agent combinations will be formed
even in the case of a small collection of therapeutic
agents. Therefore, although some experimental methods
have been launched to screen favourable drug combina-
tions by disease-relevant phenotypic assays [8], the high-
throughput identification of synergistic agent combina-
tions arising from numerous agents remains an unre-
solved issue [9]. By way of contrast, computational
approaches that take advantage of the rapid accumula-
tion of massive data may provide a more promising and
desirable method for multicomponent drug studies. Cur-
rently, computational efforts for the evaluation of multi-
component therapeutics mainly focus on two directions.
The first direction is to identify and optimize multiple
target interventions by modelling signaling pathways or
specific processes and is usually applied to small scale
problems [10,11]. One of limitations of this approach is
the fact that crosstalks, feedbacks or interactions among
pathways are widely present in complex diseases, sug-
gesting that pathways should be integrated rather than
treated separately [12,13]. The second newly developing
direction is to measure the efficacy of drugs, especially
multi-target drugs, by using network biology approaches
[14]. However, the realistic method remains to be estab-
lished and the association between drug actions and net-
work properties is not precisely known. Thus, finding
ways to evaluate multicomponent therapeutics and sort
order for synergistic agent combinations is still a consid-
erable challenge. Novel computational approaches are
urgently required for feasible and efficient identification
of multicomponent synergy.
Recently, computational systems biology approaches as
well as our previous studies have been enhancing our
understanding of various aspects of complex diseases,
including the identification of disease-related genes or
functional modules, and the recognition of redundant,
adaptable and system mechanisms in diseases [15-17].
Now, we are standing at the portal of a new era to
bridge molecular states to physiological states as well as
various disease states through the biological networks
that sense genetic and environmental perturbations [18].
To keep in line with new developments, researchers
have also started to change their way of thinking in
terms of drug-treated complex biological systems, and
studies such as network pharmacology [19] have been
springing up. Against this background, we propose a
novel concept, “network target”, with the attempt to
update current single target-based or multiple target-
based drug studies. We roughly defined the “network
target” as a therapeutic target that is derived from sys-
tematic interventions of the biological network (includ-
ing the network state and its pivotal elements)
underlying a disease or pathological process. The con-
cept of network target considers simultaneously the dis-
ease mechanisms and drug actions on a network basis,
and a network target for a certain disease may corre-
spond to a variety of single-component or multicompo-
nent therapeutics.
On the other hand, while the scientific community has
high expectations for the coming network pharmacology
[19], this new field should be composed of two main
approaches due to our poor understanding of cell beha-
viours and drug-protein interactions: 1) Bottom-up:
Addition of well-known molecular drugs and observa-
tion of synergistic effects; 2) Top-down: Reduction of
more general formulae to its minimal elements that
keep its beneficial properties. In this regard, an empiri-
cal system of multicomponent therapeutics, traditional
Chinese medicine (TCM), may have the potential of
addressing a relationship between multicomponents and
drug synergistic effects. Having been evolved over 3,000
years, TCM is characterized by the use of Herbal For-
mulae (Fu-Fang) that are usually grouped by two or
more medicinal herbs and capable of systematically con-
trolling various diseases such as angiogenic disorders
[20] via potentially synergistic herb interactions [21,22].
For instance, the Realgar-Indigo naturalis Formula has
an effect on promyelocytic leukemia via the action
mechanism of synergy among its components [23].
Thus, the multicomponent synergy in Chinese herbs is
of great significance for understanding TCM and for
new drug discovery. Although this is still an open ques-
tion, it is believed that the rich body of TCM experience
in combined use of herbs may provide an excellent
model for studying synergistic effects among different
components [24], and the systems biology approaches
could shed light on the mystery of TCM [22,25].
In this work, we report a novel method, called NIMS
(Network target-based Identification of Multicomponent
Synergy), to address the network target-based virtual
screen and assess the synergistic strength of multicom-
ponent therapeutics. NIMS measures synergistic agent
combinations by creating and integrating two para-
meters, namely Topology Score and Agent Score. Next,
NIMS was applied to prioritize synergistic combinations
from 63 agents including 61 herbs or herb compounds
as well as five agent pairs with known synergistic effects
containing 2 additional chemicals 5-fluorouracil and
Rapamycin. One of NIMS outputs was then subjected to
experimental verification. We hope the network target-
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multicomponent therapeutics in terms of complex biolo-
gical systems.
Results
Pipeline of NIMS
The rationale of the network target concept and NIMS
is to transfer the relationship among agents to the inter-
actions among the targets or responsive gene products
of agents in the context of a biological network specific
for a disease or pathological process. This hypothesis
m a yb er e a s o n a b l ei nm a n ys i t u a t i o n se s p e c i a l l yw h e n
synergy occurs only if the effects of individual agents
are mediated through independent action mechanisms.
In NIMS, a set of genes or gene products affected by an
agent are termed agent genes, and the disease-specific
biological network serves as the background network to
perform NIMS. Then, two elements in NIMS, Topology
Score (TS) and Agent Score (AS), are proposed to evalu-
ate agent interactions.
A ss h o w ni nF i g u r e1 ,TS is derived from topological
features of the background network related to certain dis-
ease conditions and drug actions. From the network tar-
get perspective, the achilles’ heel of the biological
network underlying a certain disease is more likely to
become the attack points of drugs. Thus, we assume that
the more important the agent gene as a network node is,
the stronger effect on the disease the agent will produce.
To determine the importance of an agent gene as a node
in the network, we propose a node importance score, (IP
(v), here v denotes a vertex / node), by integrating degree
[26], betweenness [27] and closeness [28], three network
centrality indexes that have been used to define the net-
work properties of drug targets separately or collectively
[29]. Moreover, we suppose that if an agent pair produces
synergy, their agent genes should be adjacent in the net-
work. Accordingly, for a candidate agent pair agent1 and
agent2, we defined a topology-dependent score, TS,t o
evaluate both the importance score (IP(v)) of agent1 genes
and agent2 genes and the network distance between these
two gene sets. TS1,2 is given by:
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where IP1(i)f o ragent1 genes and IP2(j)f o ragent2
genes are calculated by integrating Betweenness, Close-
ness and a variant of the Eigenvector PageRank [30]
through Principal Component Analysis (PCA). The
negative exponential function is utilized to weigh the
interaction of two agents based on the shortest path
length. The min(di,j) is the minimum shortest path from
genei of agent1 to all agent2 genes,w h e r e a sm i n ( dj,i)i s
the minimum shortest path from genej of agent2 to all
agent1 genes. We only consider the nearest connection
between agent1 genes and agent2 genes in the network.
The two terms in the brackets are dual and represent
the synergy strength measurement for a combination of
agent1 and agent2.
Figure 1 Pipeline of NIMS: ranking the synergistic effect of n agents paired with a given agent. For a given agent (Agentx)a n dn
candidate agents (Agent1, …, Agentn), all agent genes are collected and mapped to a disease network target. For each agent (Agent1, …, Agentn)
combined with Agentx, TS (Topology Score) is obtained by calculating the node importance of both sets of agent genes and the shortest path
between them. TS is subsequently weighed by the AS (Agent Score) of each agent pair to ultimately produce S (Synergy score), which is used to
rank the synergy strength for the n candidate agents matched with the given Agentx.
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treating similar diseases may be more likely to produce
synergistic effect, we also introduced AS,ac o n c e p t
transferred from the disease phenotype similarity [31],
to quantify the similarity score of two agents and fine-
tune the TS results. Here, if an agent gene falls into the
gene set of a phenotype recorded in the OMIM (Online
Mendelian Inheritance in Man) database, this phenotype
will be identified as an agent phenotype for the given
agent. The similarity between two agent phenotypes
quantifies the overlap of their OMIM descriptions and
is calculated by a text mining method [31] (See Meth-
ods). The AS for agent1 and agent2 is given by
AS
P
N
ij
ij
12 ,
,
, =
∑ ,w h e r ePi,j is the similarity score between
phenotypei of agent1 and phenotypej of agent2,a n dN is
the total number of phenotype pairs.
Ultimately, NIMS produces the synergy score, S1,2,f o r
agent1 and agent2 by calculating S1,2 = TS1,2 × AS1,2,
which denotes the node importance, network adjacency
and action similarity of two gene sets of agent1 and
agent2. A high score means a great probability of synergy.
Note that currently NIMS only measures the synergy of
combinational agents with independent mechanisms
according to the Bliss independent theory [5], so we
r o u g h l ys e tt h ev a l i dr a n g eo ft h eN I M Ss c o r ef r o m0t o
0.9. When the score is larger than 0.9, the two agents in
combination are more likely to act on the same gene sets
and in contradiction with the independence assumption.
For these agent combinations, we may need more infor-
mation to distinguish their interaction modes.
Application and experimental verification of NIMS
We applied NIMS to prioritize synergistic agent pairs
from 63 manually collected agents (See Methods)a n d
estimated their effects on angiogenesis, a key pathologi-
cal process in various diseases such as cancer and rheu-
matoid arthritis [32], with the network constructed by
our LMMA approach previously [17]. The NIMS
synergy scores for all agent pairs against the angiogen-
esis network ranged from 0.199270 to 0.012959, with TS
score from 0.814868 to 0.103790 and AS score from
0.262459 to 0.107882, respectively. From the outputs of
NIMS, we firstly checked the rank of five agent pairs
with known synergy in every 62 pairs for a given agent.
As shown in Table 1, the synergy scores of both 5-fluor-
ouracil (5-FU) combined with Vinblastine [33] and 5-FU
combined with Rapamycin [34] entered the top three.
Three other synergistic pairs, Vinblastine and Camp-
tothecin [35], Genistein and Camptothecin [36], and
Genistein and Rapamycin [37], also earned high marks
and ranked in the top layer. We then used, respectively,
three global background networks including the global
protein-protein interaction (PPI) network and two kinds
of global pathway networks (Keep Node Content and
M e r g eN o d eC o n t e n t ,K N Ca n dM N C )( See Methods)
to calculate the synergy score. Results showed that
NIMS is relatively robust to different background net-
works in these cases (Table 1).
Next, an in vitro assay was conducted to validate NIMS
predictions. Sinomenine, an anti-angiogenic alkaloid that
extracted from a TCM commonly used herb named Sino-
menium acutum[20,38], was selected as the seed agent
(as Agentx in Figure 1). Agent combinations were
sampled from five intervals of the rank list composed of
all 62 agents matched with Sinomenine. Here, we only
considered commercially available agents with known
chemical structures. This restriction left five Sinomenine
partners, namely Luteolin, Quercetin, Honokiol, Matrine
and Paeoniflorin. To determine the synergy strength of
the agent pairs, low-dose combinations with more than a
Table 1 NIMS ranks against four types of background networks
Rank among 62 agent pairs #
Given agent Partner agent Angiogenesis network (NIMS score) PPI KNC MNC
5-fluorouracil Vinblastine* 2 (0.18104) 1 2 2
Rapamycin* 3 (0.13744) 2 3 26
Vinblastine Camptothecin* 1 (0.19927) 1 1 3
Genistein Camptothecin* 2 (0.12070) 3 2 2
Rapamycin* 6 (0.11533) 4 7 4
Sinomenine Matrine 4 (0.10923) 6 3 11
Honokiol 8 (0.10142) 5 9 16
Luteolin 10 (0.10007) 11 17 6
Quercetin 14 (0.09835) 20 5 3
Paeoniflorin 29 (0.08215) 26 29 31
*: Agent pairs with known synergistic effects.
#: For each given agent, there are totally 62 candidate agent pairs. PPI, protein-protein interaction network. KNC, Keep Node Content pathway network. MNC,
Merge Node Content pathway network.
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the Maximum Increased Inhibition Rate (MIIR) measure
for each combination (Figure 2), we found that the high-
est MIIR 26.83% was reached by Sinomenine combined
with Matrine ((S):(M)), whereas the lowest MIIR 1.86%
was reached by Sinomenine combined with Paeoniflorin
((S):(P)). This rank order of agent pairs is identical to the
order predicted by NIMS when against the angiogenesis
network, and such a performance is superior to those
against three global networks (Table 1).
Robustness of NIMS
NIMS integrated three measures, namely Betweenness,
Closeness and PageRank to capture the node importance
IP(v) from different aspects. In the undirected angiogen-
esis network, we found that all three measures are highly
Figure 2 A n t i - a n g i o g e n e s i ss y n e r g i s t i ce f f e c t so ff i v ea g e n tp a i r s .a - e .The red line denotes the inhibition rate of Human Umbilical Vein
Endothelial Cells (HUVEC) proliferation in a dose-dependent manner. The blue line denotes the additive effects calculated by the Bliss
independence model. The gray column denotes the optimal dose and ratio of each pair. f. The value of the maximum increased inhibition rate
(MIIR) for the synergistic effects produced by five agent pairs corresponds well with the NIMS ranks against the angiogenesis network. The
proportion of two agents is determined by following the same ratio of the two agent’s IC50 values.
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be explained by the primary eigenvector. However, these
three centrality measures could not replace one another,
especially in the directed networks. Thus, we integrated
these three centrality measures to address the node
importance from different angles. Furthermore, the posi-
tive role of AS in NIMS was also shown in the agent pair
r a n k i n g s .I nt h ec a s es t u d y ,t h eAS scores of Matrine,
Honokiol, Luteolin, Quercetin and Paeoniflorin sepa-
rately combined with Sinomenine were 0.1708, 0.1590,
0.1705, 0.1611 and 0.1414, respectively. These scores
r e a c h e da na p p r o x i m a t er a n kw i t ht h a tr e s u l t e df r o m
network topologies alone. The removal of the AS scores
ranked Luteolin ahead of Quercetin, suggesting that the
integration of AS, which reflects current knowledge
about complex diseases and agent actions, could improve
the predictive accuracy of NIMS by weighing TS.
The robustness of NIMS was also addressed with
respect to both agent genes and the background net-
work. By adding or removing agent genes randomly, the
permutation test results showed that the Spearman
Rank Correlation Coefficient (SRCC) was relatively
stable when adding genes, but the SRCC decreased dra-
matically when some key genes were removed (Figure
3a and Figure 3b). The results evidence that the NIMS
synergy score may be determined largely by some key
agent genes, and the rank results will remain stable as
long as these key genes are retained. Such phenomena
also agree well with that the power law networks are
robust with respect to deletion of random nodes, but
fragile with respect to deletion of hubs [40]. Moreover,
by deleting or importing additional interactions at differ-
ent percentages in the angiogenesis network, we found
that the NIMS outputs were quite stable even when 50%
of the edges were randomly removed or added (Figure
3c), indicating that NIMS is insensitive to both incom-
pleteness and noise regarding the background network.
Comparison with meet/min
To determine whether the synergy rank of agent pairs
c o u l db eo b t a i n e df r o mc o r r e s p o n d i n gagent genes
alone, regardless of network knowledge, we used the
meet/min method, a similarity measurement between
two gene sets that discards the network information
[41], to rank the agent pairs. The meet/min method is
b e l i e v e dt ob es i m p l eb u te f f e c t i v ea n dn o n - b i a s e d[ 4 1 ] .
Because the NIMS score and the meet/min coefficient
(ranging from 0 to 1) will both reach their maximum
w h e nt h eg e n es e to fo n ea g e n ti sm e r e l yt h es u b s e to f
that of the other agent, we only investigated agent com-
binations with valid scores from 0 to 0.9. In general, a
relatively high correlation (SRCC=0.6251) between the
meet/min coefficient and the NIMS synergy score was
observed for all agent pairs. However, compared with
the experimental results, the performance of the meet/
min method was relatively poor in ranking synergistic
pairs with Sinomenine (Table 2).
NIMS synergy and GO function
We measured Gene Ontology (GO) co-annotations to
advance understanding of the underlying synergy
mechanism for agent pairs predicted by NIMS. All three
GO categories, Biological Processes, Cellular Compo-
nents and Molecular Functions, were considered. As
shown in Table 3, weak correlations were observed
between the NIMS synergy scores and the GO similarity
scores calculated from genes of each agent pairs. Results
showed that agents with synergy may not target the
same functional processes.
Features of synergistic agent combinations on the
angiogenesis network target
Practically, we treat the angiogenesis network target as
core subnetworks of angiogenesis network which contains
the intersection of a set of shortest path subnetworks
Figure 3 Permutation tests to assess the robust performance of NIMS. The permutations are performed by evaluating fluctuations of (a) TS
(Topology Score), (b) AS (Agent Score), and (c) the background network (angiogenesis network) and calculated by the average SRCC (Spearman
rank correlation coefficient) between the permutation outputs and the original scores.
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To learn the exact features on the angiogenesis network
target derived from agent combinations with different
NIMS scores, we mapped the responsive genes of 5-flour-
ourcil, Vinblastine, Sinomenine, Matrine and Paeoniflorin
to the network target and the detailed network features
especially pathway crosstalks and feedback loops were ana-
l y z e d .A ss h o w ni nF i g u r e4 ,w ef o u n dt h a tt h en e t w o r k
target could capture different synergistic responses
induced by three agent combinations with different NIMS
synery scores. For example, 5-flourourcil and Vinblastine
can affect KDR protein complex, the crosstalk between
AKT1 and MAPK1 pathways, the PTEN feedback loop as
well as two biological processes, endothelial cell prolifera-
tion and apoptosis, and four hub nodes (KDR, MAPK1,
JUN and TP53). The network target affected by Sinome-
nine and Matrine contains the crosstalk with EGFR, KDR
and TNFRSF1A pathways, the PTEN feedback loop, as
well as, four biological processes closely associated with
angiogenesis and two hub nodes (JUN and TP53). How-
ever, Sinomenine and Paeoniflorin with lower synergy
score can only affect two biological processes and one hub
node (TP53) (Figure 4).
Characterizing the mechanisms of multicomponent
synergy from a network target perspective
Despite the widespread occurrence of multicomponent
therapeutics, the molecular mechanisms that underlie
drug synergy remain unclear. Based on the above com-
putational and experimental results of NIMS, we
demonstrate that the network target can nicely interpret
the multicomponent synergy by its latent network
topology properties. We hence give a generalization of
the network target concept and NIMS parameters to
formalize our viewpoints on drug synergistic mechan-
isms. As shown in Figure 5, the shortest path distance
(min(di,j) in NIMS) can describe the protein complexes,
crosstalks as well as feedback loops in the network
formed by genes associated with two agents (Figure 5a),
the hub and betweenness (IP(v) in NIMS) denotes the
importance of genes or stimuli-influenced number of
molecules two agents affected (Figure 5b), and func-
tional modules means the biological processes two
agents targeted (Figure 5c). It is important to note that
these findings match well with the synergy phenomena
present in complex biological systems. The available evi-
dences showed that molecular synergisms can be
emerged from different aspects, for example, protein
complexes in cell-regulatory systems [42], crosstalk
[43-47] and feedback control in the structures of signal
pathways [48,49], stimuli-influenced number of mole-
cules (e.g. number of activated enzymes, receptors,
channels or transcription factors) [50,51] and gene
expression profile [52] in signal transduction process.
Thus, from the network target perspective, we can gain
a comprehensive understanding of drug synergistic
mechanisms on the basis of complex biological systems.
Discussion
Recently, with the growing understanding of complex
diseases, the focus of drug discovery has shifted from
the well-accepted “one target, one drug” model designed
t o w a r das i n g l et a r g e tt oan e w“multi-target, multi-
drug” model aimed at systemically modulating multiple
targets [19,53]. In this work, we proposed the concept
of “network target”, which treats the disease-specific bio-
logical network and its key elements as a therapeutic
target, and established a NIMS approach to prioritize
the multicomponent synergy. NIMS combines network
topology and agent similarity, with regard to agent
genes as well as phenotypes. To demonstrate the cap-
ability of NIMS, we applied this algorithm to the priori-
tization of synergistic anti-angiogenesis agent pairs from
an empirical multicomponent therapeutic system, TCM.
Our results show that NIMS, especially when used
Table 2 Synergy ranks of five Sinomenine pairs resulted from NIMS, meet/min and cell experiment
Agent matched with Sinomenine NIMS rank The meet/min rank Experimental rank
AS × TS TS AS
Matrine 4 5 10 20 1
Honokiol 8 6 32 19 2
Luteolin 10 21 12 21 3
Quercetin 14 14 26 29 4
Paeoniflorin 29 22 52 6 5
AS, Agent Score; TS, Topology Score.
Table 3 Correlation of the NIMS synergy score with agent
genes’ GO co-annotations
Correlation of the NIMS score with GO similarity
score
Categories Biological
Processes
Cellular
Components
Molecular
Functions
SRCC 0.1649 0.0641 0.1571
p-value of
SRCC
0.1963 0.617 0.2182
GO, Gene Ontology; SRCC, Spearman Rank Correlation Coefficient.
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cessfully recover known synergistic drug pairs (Table 1),
but also rank the anti-angiogenesis synergistic agents
matched with a given agent, Sinomenine (Figure 2).
Interestingly, two synergistic agent pairs predicted by
NIMS in the case study, Sinomenine and Matrine, and
Sinomenine and Honokiol, respectively, are main consti-
tuents of TCM herbal formulae such as Qing-Luo-Yin
[38]a n dTou-Gu-Zhen-Feng pill. These preliminary
results demonstrate the potential of NIMS as a tool for
screening synergistic combinations from current drugs
as well as TCM herbs or herbal formulae.
NIMS uses the agent gene and phenotype information
plus network topology features. We demonstrated that
NIMS is robust to the collected agent genes if the key
genes are reserved (Figure 3a and Figure 3b). Moreover,
NIMS is also relatively robust to the background net-
work, although available networks such as the PPI net-
work are still incomplete and biased (Figure 3c) [54].
We consider the following aspects of NIMS may contri-
bute to such robust performances. (1) The gene set
information of agents not only reflects the knowledge of
agent action similarity, but also determines the meet/
min coefficient. We detected a potential correlation
between the meet/min coefficient and the NIMS score.
Thus the agent gene information itself ensures a rela-
tively stable performance of NIMS against different
types of networks. (2) The inherent agreement of topo-
logical features, a critical element in ranking synergistic
agent pairs, is embedded in the angiogenesis, HPRD and
KNC networks. On the contrary, poor performance is
seen when the network topology is fundamentally
altered, as in the MNC pathway network (Table 1).
Note that the MNC pathway network is constructed in
ad i f f e r e n tw a y( See Methods for details). (3) NIMS
only makes use of a small fraction of the network
around the network targets. Thus, it is relatively insensi-
tive to changes of the whole background network but
Figure 4 Features of synergistic agent combinations on the angiogenesis network target. a. 5-flourourcil and Vinblastine with known
synergy. b. Sinomenine and Matrine with the high NIMS synergy score. c. Sinomenine and Paeoniflorin with the low NIMS synergy score. The
nodes with red or blue colour denote responsive genes associated with two agents respectively.
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Page 8 of 13Figure 5 A network target perspective for understanding the mechanisms of multicomponent synergy. a. Two agents targeting a
protein complex, the feedback loop or crosstalk in a signaling network (the left figure) may have the shortest path distance and obtain high
NIMS synergy score compared to those do not (the right figure). b. Two agents targeting hub or betweenness nodes (the left figure) may
produce higher synergism than the combinations targeting peripheral nodes (the right figure). c. Two agents targeting two compensatory
modules related to one disease or the similar diseases (the left figure) may produce higher synergism than those targeting two unrelated
modules from unrelated diseases (the right figure). Dashed lines represent direct or indirect connections in a network. Blue or red nodes denote
the responsive genes of two agents respectively.
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lines the importance of the network target as a deter-
mining factor responsible for both disease mechanisms
and agent actions in a network level.
We also evaluated the underlying synergy strengths
produced by agent pairs from the perspective of GO
functions. For 62 agents matched with Sinomenine,
there is relatively lower correlation between NIMS
synergy scores and GO co-annotations (Table 3). This
finding is not surprising, because synergistic effects in
multicomponent therapeutics could be achieved by
genes that are involved in different biological processes
related to a disease [1]. A disease or pathological condi-
tion is also characterized by the involvement of complex
biological processes with hierarchical organization.
Hence, synergistic agent pairs may not be restricted to
act on the same biological functions.
Based on the above results, we further investigated the
effects on the angiogenesis network target illustrated by
three agent combinations with different NIMS synergy
scores, namely 5-flourourcil and Vinblastine, Sinome-
nine and Matrine, and Sinomenine and Paeoniflorin
(Figure 4), and characterized the multicomponent syner-
gistic mechanisms from a network target perspective
(Figure 5). Interestingly, we found that the network tar-
get coupling with NIMS parameters can capture the
potential drug synergistic mechanisms from many
aspects covering protein complexes, crosstalk and feed-
back loop of pathways, and stimuli-influenced molecular
number [42-52], demonstrating the network target
could serve as a new mode of drug target and the NIMS
method is reasonable for identifying drug synergy. Such
features also make NIMS compatible and upgradeable
with other small-scale or large-scale network methods
regarding drug action mechanisms we developed
recently [9,55][22].
NIMS is a vital part in our NIDA (Network target-
based Identification of Drug Action and drug synergy)
system [56]. In previous studies, we demonstrate that
this system can also be used to prioritize effects of can-
didate drugs / herbs on one or more biological pro-
cesses related to given diseases [57]. To improve further
the quality and performance of NIMS, there are three
issues to be considered. First, the network target for a
specific disease can be generated by disease-causal gene
networks, disease-responsive gene networks or drug tar-
get networks. Due to the lack of understanding of com-
plex diseases, here we only adopt the responsive gene
network associated with a given disease or pathological
process such as angiogenesis. It is believed that the
more precise the network target is chosen, the more
accurate predictions will be obtained, as suggested by
the comparison results between the angiogenesis net-
work and three global networks. We will also evaluate
more useful parameters such as subgraph centrality and
information centrality to calculate the node importance
in both directed and undirected networks [58]. Addi-
tionally, the prediction obtained by NIMS may also be
improved if we make use of more information such as
the network Yin-Yang imbalance [25] or the side-effect
information to refine the network target.
Second, though we only conducted the pure com-
pounds to experimental studies, NIMS actually can be
flexibly used to multiple ingredients in each herb as long
as the related genes (agent genes) are available and reli-
able. To extend NIMS to more complicated conditions
or more than two agents, we can treat mixed agents such
as herb extracts and herbs as a group of compounds, and
the predicted ranks of NIMS depend only on what agent
genes are inputted and how accurate the agent genes are.
For agent genes, the present work merely considered
responsive genes associated with a limited number of
TCM agents. Hopefully, NIMS can be updated when
more precise information on drug targets is revealed for
more agents by experiments or recent developed predic-
tion tools such as drugCIPHER [55].
Third, as an initial effort for prioritizing synergistic
agent combination in a computational framework,
NIMS currently is a little bit simplified since it considers
only part of the synergistic effects at the molecular level
and currently does not make the distinction between
the synergistic and antagonistic effects. The tissue-level
synergism did not enter into our calculations. Further
studies will be devoted to quantitative analysis of
synergy, tissue-level synergy analysis, and pattern com-
parison between synergism and antagonism by integrat-
ing multilayer -omic data and spatio-temporal
information. The identification of the cooperative beha-
v i o u r sa n dm e c h a n i s m so fm u l t i p l ea g e n t sa sw e l la s
corresponding network targets will also be examined by
both in vitro and in vivo experiments.
Conclusions
In summary, our work demonstrates that the network
target-based methods are of importance for estimating
synergistic combinations and facilitating the combina-
tional drug development. NIMS can serve as a first-step
computational approach for the high-throughput identi-
fication of multicomponent synergy and the moderniza-
tion of traditional Chinese medicine. It is also a
promising way to elucidate the inter-relationship
between complex diseases and drug interventions
through the network target paradigm.
Methods
Data preparation
To obtain the empirical multicomponent candidates, 49
TCM herbs and 12 herb-derived compounds with
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tumor activities were selected from the 2005 Edition of
Chinese Pharmacopoeia, an official compendium of
drugs, covering traditional Chinese herbs, herbal formu-
lae and western medicines.Two chemicals 5-fluorouracil
and Rapamycin were also included and resulted in a
total of 63 agents. Five agent pairs among them were
reported synergistic action and retrieved as benchmark
data for NIMS outputs. By reading more than 2,000
references regarding agent actions from both PubMed
and the China National Knowledge Infrastructure
(http://www.cnki.net), available agent genes and agent
phenotypes were manually collected. The number of
genes for each agent ranged from 10 to 108. A total of
736 non-redundant agent genes were obtained. For cal-
culating Agent Score (AS), we collected the agent pheno-
type similarity scores from the study of van Driel et al
[31], in which the similarity score between two pheno-
types is determined by the cosine of their feature vector
angle, and the reliability of the score has also been
tested [31].
Angiogenesis network construction and three global
networks
The angiogenesis gene network was constructed by the
LMMA method we developed previously [17]. By using
the keyword “Angiogenesis OR Neovascularization”,w e
retrieved 49,885 PubMed abstracts (until Feb 9, 2007),
in which 2,707 genes were identified with Entrez gene
ids and served as nodes of the angiogenesis network.
Two genes were considered linked if they had any rela-
tionship in the PPI from HPRD (release 7) [59] or path-
way interactions from KEGG [60]. We also employed
three types of global networks, the PPI network and two
types of global pathway networks merged from 201
KEGG human pathways, to evaluate the robustness of
NIMS in terms of the background network. In KEGG,
one node within a KEGG Orthology (KO) may denote a
group of genes/proteins, and one gene may belong to
different KOs. For example, K01090 contains 26 human
genes, and the gene CDKN3 is categorized in both
K01090 and K01104. Therefore, we built two distinct
pathway networks: the Keep Node Content pathway net-
work and the Merge Node Content pathway network. In
the KNC network, the original node content was kept
consistent, whereas in the MNC network, different KOs
w i t ho n eo rm o r eo v e r l a p p i n gg e n e sw e r em e r g e di n t o
one node.
NIMS robustness analysis
By changing the parameters and then calculating the
correlation between the new and original NIMS scores,
we checked whether NIMS could perform robustly. All
three centrality measures (Betweenness, Closeness and
PageRank) for TS and the role of AS were analyzed.
Then, we conducted permutation tests and measured
SRCC between the permutated and original TS or AS
scores for the changes of collected agent genes as well as
the background networks. In this step, agent genes were
removed or added randomly from the angiogenesis net-
work, changing 10% of the genes at a time. Each itera-
tion of adding or removing genes was repeated 100
times. For angiogenesis network, we randomly deleted
edges and imported additional edges respectively at dif-
ferent percentages, each repeated 20 times, and mea-
sured the synergy score.
NIMS synergy and GO function analysis
To examine the association between biological functions
and the NIMS predicited synergy, we used permutation
tests and SRCC to evaluate whether the genes related to
the synergistic agent pairs predicted by NIMS tended to
have co-annotations in GO [61]. We used the Union-
Intersection (UI) score to analyze the GO functional
similarity for genes from each agent pair. The UI score
was calculated by the GOstats package in Bioconductor
[62], defined as UI
GOs g GOs g
GOs g GOs g
gg 12
12
12
,
__
__
=

 ,w h e r e
GOs_g1 and GOs_g2 are the GO annotation term sets of
agent1 genes and agent2 genes, respectively.
Angiogenesis in vitro assay
We employed the commonly-used Endothelial Cell Pro-
liferation assay to verify NIMS predicted synergistic
effects on angiogenesis. Human Umbilical Vein
Endothelial Cells were obtained from Cascade Biologics
(Portland, USA), cultured in Medium 200 (Cascade Bio-
logics), supplemented with low serum growth supple-
ment including 2% fetal bovine serum and a well-
documented angiogenic growth factor bFGF (5 ng/ml)
stimulus. Sinomenine and the sampled partner agents
were purchased from the National Institute for the Con-
trol of Pharmaceutical and Biological Products, Beijing,
China. The concentration range of each agent was
o b t a i n e df r o ml i t e r a t u r ea n dt h eI C 5 0v a l u e( t h eh a l f
maximal inhibitory concentration) for each individual
agent was measured. To compare the interacted agents
under the same effect level, we determined the propor-
tion of each agent pair by following the same ratio of
the two agent’s IC50 values. For example, if the IC50
values of agent1 and agent2 are 10 and 100 respectively,
we set the proportion of this agent pair as 1:10 in verifi-
cation experiments. Each treatment was administrated
after cell growth for 24 hours in a 96-well plate. Cell
proliferation was estimated using a Cell Counting Kit
( C C K - 8 ,D o j i n d o ,J a p a n )a f t e r4 8h o u r so ft r e a t m e n t .
Each experiment was repeated three times. By using the
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was determined by calculating: MIIR=max(IRsyn–IRadd),
where IRsyn and IRadd denote inhibition rates and the
Bliss additive value of an agent pair at a certain dose/
ratio.
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